Mohsen Isaac, MD
Radiation Oncology · Monongahela, PANPI 1225035348
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.4%), food and beverage and education — rather than concentrated in one kind of arrangement. Elekta, Inc. accounts for 71.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $758 and has fallen 85.3% since, to $111 in 2025.
Across 13 payments — averaging $94.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elekta, Inc.$870
- Novocure Inc.$130
- Elekta Instrument AB$89
- Pfizer$40
- Progenics Pharmaceuticals, Inc.$25
- Daiichi Sankyo Inc.$22
- plus $48 from 3 others
What the payments were for
- Travel & lodging$67855%
- Food & beverage$50741%
- Education$403%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elekta, Inc. | 5 | $870 |
| Novocure Inc. | 1 | $130 |
| Elekta Instrument AB | 1 | $89 |
| Pfizer | 1 | $40 |
| Progenics Pharmaceuticals, Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| Medline Industries LP | 1 | $15 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,225 in reported general payments places this provider in the 65th percentile of 339 radiation oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 22 | $33 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Monongahela
- Chirag ShahPittsburgh$344K
- Neil TaunkPhiladelphia$203K
- Wenyin ShiPhiladelphia$119K
- Navesh SharmaYork$106K
- Zachary HornePittsburgh$56K
- Yvonne MoweryPittsburgh$55K
- Kevin NeadPhiladelphia$50K
- Adam DickerPhiladelphia$46K
- Ajay BhatnagarHershey$42K
- Tinatin ChabrashviliPhiladelphia$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.